24/7 Market News Snapshot 12 September, 2025 – Anebulo Pharmaceuticals, Inc. Common Stock (NASDAQ:ANEB)

September 12, 2025

DENVER, Colo., 12 September, 2025 (www.247marketnews.com) – (NASDAQ:ANEB) are discussed in this article.
Anebulo Pharmaceuticals, Inc. (ANEB) is currently experiencing a noteworthy bullish trend in the pre-market session, with shares trading at $2.365, marking a robust increase of approximately 17.66% compared to the previous close of $2.010. This upsurge is buoyed by a substantial trading volume, reaching 519.14K shares, which points to significant market interest and positive investor sentiment. Market analysts suggest closely monitoring resistance levels near $2.50 and support around $2.00 to better gauge potential future price movements. Investors are advised to consider volatility and prevailing market conditions before making any financial commitments.

In a strategic update, Anebulo has announced its intent to explore a going private transaction, a decision that has piqued interest from various financial and strategic partners. This initiative underscores the company’s commitment to maximizing stockholder value, as its Board of Directors conducts a thorough review of available strategic options. These alternatives include assessing the potential for the going private transaction, a possible asset sale, or a merger, in addition to a proposed reverse stock split. While the company aims to finalize these decisions, it has not established a definitive timeline for completion.

To further engage shareholders, Anebulo will convene a special stockholder meeting, where the proposed reverse stock split will be presented for approval. The Board retains the discretion to abandon this split based on shareholder feedback and ongoing strategic evaluations. Moreover, Anebulo continues to advance its product development pipeline, particularly focusing on an intravenous formulation of its lead candidate, selonabant, which targets pediatric patients experiencing acute cannabis-induced toxicity. This strategic direction reflects Anebulo’s dedication to addressing critical healthcare challenges while pursuing expedited regulatory approval. Stakeholders are encouraged to stay informed as further developments unfold.

Related news for (ANEB)

NASDAQ and NYSE quotes and data are delayed 15 minutes unless indicated otherwise. Market data and exchange information are provided for informational purposes only and is not intended for trading purposes. Neither 24/7 Market News Editors, 247 Market News, or data and content providers shall be liable for any errors or omissions, delays, misquotes or other market information relayed in any press materials. You should Use Realtime data to conduct due diligence before investing or trading, and trading in any stock is risky you could lose all your money.